Trade Vanda - VNDA CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position-0.026179 %(-$1.05)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position0.003957 %($0.16)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-$1.05)

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  ($0.16)

Key Stats

• Prev. Close: 4.8
• Open: 4.75
• 1-Year Change: -22.39%
• Day's Range: 4.69 - 4.77

Vanda Company profile

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vanda Pharmaceuticals Inc. revenues increased 8% to $268.7M. Net income increased 42% to $33.2M. Revenues reflect Hetlioz segment increase of 8% to $173.5M, Fanapt segment increase of 9% to $95.1M. Net income benefited from Selling, General and administrative - decrease of 10% to $105.9M (expense), Advertising Expenses decrease of 47% to $6.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 150M auth., 28,103,441 issd. Insiders own 1.56%. 4/18/06 IPO: 5.8M shs. @ $10 per shareby JP Morgan Securities, Inc.